Results 131 to 140 of about 1,506 (153)
Some of the next articles are maybe not open access.
The Role of Lebrikizumab in the Treatment of Atopic Dermatitis in the Adult Population
Immunotherapy, 2023Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD.
Stuti Prajapati +3 more
openaire +2 more sources
pharma-kritik
Lebrikizumab: Ein Interleukin-13-Hemmer. ebenfalls mit der Indikation einer schwierig behandelbaren atopischen Dermatitis. Er ist dabei ähnlich wirksam wie andere systemisch verabreichte Wirkstoffe. Wie unter Dupilumab tritt auch unter diesem IL-Hemmer häufig eine Konjunktivitis auf.
openaire +1 more source
Lebrikizumab: Ein Interleukin-13-Hemmer. ebenfalls mit der Indikation einer schwierig behandelbaren atopischen Dermatitis. Er ist dabei ähnlich wirksam wie andere systemisch verabreichte Wirkstoffe. Wie unter Dupilumab tritt auch unter diesem IL-Hemmer häufig eine Konjunktivitis auf.
openaire +1 more source
Drugs
Lebrikizumab (Ebglyss®) is a subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody developed by Almirall S.A. and Eli Lilly and Company for the treatment of atopic dermatitis (AD). In November 2023, lebrikizumab was approved in the EU for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older with a body ...
openaire +2 more sources
Lebrikizumab (Ebglyss®) is a subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody developed by Almirall S.A. and Eli Lilly and Company for the treatment of atopic dermatitis (AD). In November 2023, lebrikizumab was approved in the EU for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older with a body ...
openaire +2 more sources
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss should not be reimbursed by public drug plans for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those ...
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss should not be reimbursed by public drug plans for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those ...
openaire +1 more source
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and TherapeuticsThe FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg).
openaire +2 more sources
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
New England Journal of Medicine, 2023Brandon, Smith +2 more
openaire +2 more sources
Lebrikizumab bei atopischer Dermatitis
DMW - Deutsche Medizinische Wochenschrift, 2023openaire +1 more source
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Skin therapy letterAtopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that inhibits the activity of interleukin-13.
Leah, Johnston +2 more
openaire +1 more source